The financials
OPKO Health, Inc. by the numbers
OPKO Health, Inc. (OPK) reported revenue of $124M in Q1 2026 (quarter ended March 31, 2026), down 17% from the same quarter a year earlier. That came with a gross margin of 37% and net loss of $55M. For the full year FY2025, revenue was $607M (−15% year on year) and net income −$226M. Its largest product in 2026-Q1 was Service at $72M, 64% of the disclosed total, just ahead of Intellectual Property And Other at 12%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $124M | $150M | −17% |
| Gross profit | $46M | $43M | +7.4% |
| Operating income | −$51M | −$67M | n/a |
| Net income | −$55M | −$68M | n/a |
| Diluted EPS | −$0.07 | −$0.10 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Service | $72M | 64% |
| Intellectual Property And Other | $14M | 12% |
| Transfer Of Intellectual Property And Other | $14M | 12% |
| Rayaldee | $13M | 11% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $113.0M (-23%)
Transfer Of Intellectual Property And Other grew +14% year on yearService -30% year on year
Segment Latestquarter on quarteryear on year
- Service$72.2M$72.2MQoQ -24%year on year -30%-24%-30%
- Intellectual Property And Other$14.0M$14.0MQoQ -25%year on year +14%-25%+14%
- Transfer Of Intellectual Property And Other$14.0M$14.0MQoQ -26%year on year +14%-26%+14%
- Rayaldee$12.8M$12.8MQoQ -14%year on year -2.3%-14%-2.3%
- Royalty--QoQ -year on year ---
Diagnostics & Research
Ranks #15 of 29 by Smart Score